Buflomedil

From Wikipedia, the free encyclopedia
Jump to navigation Jump to search

Template:Use dmy dates <templatestyles src="Chembox/styles.css"/>

Template:Chembox image cellTemplate:Chembox AllOtherNamesTemplate:Chembox headerbarTemplate:Chembox IndexlistTemplate:Chembox JmolTemplate:Chembox ChEMBLTemplate:Chembox ECHATemplate:Chembox E numberTemplate:Chembox IUPHAR ligandTemplate:Chembox UNIITemplate:Chembox CompToxTemplate:Chembox headerbarTemplate:Chembox headerbarTemplate:Chembox HazardsTemplate:Chembox Datapage checkTemplate:Yesno
Buflomedil
Template:Longitem Template:Unbulleted list
ChEBI Template:Unbulleted list
ChemSpider Template:Unbulleted list
DrugBank Template:Unbulleted list
EC Number Template:Unbulleted list
KEGG Template:Unbulleted list
Template:Longitem Template:Unbulleted list
RTECS number Template:Unbulleted list
Script error: No such module "collapsible list".
Script error: No such module "collapsible list".
Template:Longitem C17H25NO4
Molar mass 307.38 g/mol
Template:Longitem C04AX20 (WHO)

Template:Chembox Footer/tracking container onlyScript error: No such module "TemplatePar".Template:Short description

Buflomedil, sold under the brand name Loftyl, is a vasoactive drug used to treat claudication or the symptoms of peripheral arterial disease. It is currently not approved by the Food and Drug Administration (FDA) for use in the United States.

Toxicity

This drug has been suspended from marketing in the European Union, because of concerns about severe neurological and cardiac toxicity.[1][2] In its press release dated 17 November 2011 EMA suggested that doctors "should stop using buflomedil and consider alternative treatment options". The European Commission advised all member states to revoke marketing authorisation.[3]

Various adverse effects have been reported to the FDA.[4]

Synthesis

File:Buflomedil synthesis.svg
Patent:[5] China1 China2

Acylation between 1,3,5-trimethoxybenzene [621-23-8] (1) and 4-pyrrolidinobutyronitrile [35543-25-0] (2) occurs in chlorobenzene solvent in the presence of gaseous hydrochloric acid to give Bufomedil (3). This is a demonstration of the Hoesch reaction.

References

<templatestyles src="Reflist/styles.css" />

  1. Script error: No such module "citation/CS1".
  2. Archived copy EMA Template:Webarchive
  3. Script error: No such module "citation/CS1".
  4. Script error: No such module "citation/CS1".
  5. DE2122144 idem Louis Lafon, U.S. patent 3895030 (1975 to Orsymonde);

Script error: No such module "Check for unknown parameters".

Script error: No such module "Navbox". Template:Adrenergic receptor modulators